A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720

NCT01578330 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis
Relapsing-Remitting

Interventions

DRUG: Fingolimod

Sponsor

Novartis Pharmaceuticals